MedTrace Logo

Clinical Verification of Peptide Biomarkers for Human Aging

NCT02166307 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 253

Last updated 2014-06-18

No results posted yet for this study

Summary

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Conditions

  • Aging

Sponsors & Collaborators

  • Beijing Institute of Technology

    lead OTHER

Principal Investigators

  • Yulin Deng, Ph.D · School of Life Science, BIT

Eligibility

Min Age
23 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166307 on ClinicalTrials.gov